Tabelecleucel

所属图书：中国制药工业发展报告（2023） 图书作者：中国化学制药工业协会 刘敬桢 胡建伟 温再兴 潘广成 曲继广 出版时间：2023年09月 所属丛书： 在线阅读 生成引文 加入收藏 报告字数：0字 报告页数：10页 摘要 据Nature的分析报告，截至2022年4月15日，全球在研细胞治疗产品管线有2756条，同比增长36%（见图5）3393616。其中，CAR-T疗法是免疫细胞疗法研究中最广泛、发展最为成熟的方法，目前已有8款产品获批上市（见表2、表3）。2022年，全球的免疫细胞疗法不断取得突破。1月，首款TCR-T产品Kimmtrak在美国获批上市，用于治疗不可切除性或转移性葡萄膜黑色素瘤（mUM）（每瓶售价为18760美元，每名患者平均费用为40万美元，前三季度总销售额为7450万英镑3393617）；2月和5月，传奇生物的西达基奥仑赛注... 据Nature的分析报告，截至2022年4月15日，全球在研细胞治疗产品管线有2756条，同比增长36%（见图5）3393616。其中，CAR-T疗法是免疫细胞疗法研究中最广泛、发展最为成熟的方法，目前已有8款产品获批上市（见表2、表3）。2022年，全球的免疫细胞疗法不断取得突破。1月，首款TCR-T产品Kimmtrak在美国获批上市，用于治疗不可切除性或转移性葡萄膜黑色素瘤（mUM）（每瓶售价为18760美元，每名患者平均费用为40万美元，前三季度总销售额为7450万英镑3393617）；2月和5月，传奇生物的西达基奥仑赛注射液分别在美国、欧盟获批上市，成为中国首个自主研发并在海外上市的细胞治疗产品；12月20日，Atara Biotherapeutics和Pierra Fabre的免疫疗法Ebvallo在欧盟获批上市，成为全球首项获批的同种异体T细胞免疫疗法，标志着基于T细胞的免疫疗法进入新的阶段。同时，国内有3家公司的CAR-T产品已提交新药上市申请（NDA）（见表4）。 图5 2020～2022年各种细胞疗法开发管线的比较 表2 FDA批准上市的免疫细胞治疗产品 表3 中国药 << >> 作者简介

WASHINGTON, March 26, 2026 /PRNewswire/ -- Today, the Taxpayers Protection Alliance (TPA) released a report, "Blocking Breakthroughs: Delays and Denials at the FDA," highlighting the many issues with the Food and Drug Administration's (FDA's) drug approval process. The report comes amid continued controversy over the agency insisting on unrealistic and ethically-fraught criteria for approvals and walking back a bizarre decision to refuse to examine an application by Moderna for its first mRNA seasonal flu vaccine. Fortunately, FDA Center for Biologics Evaluation and Research Director Vinay Prasad—who played a key role in these decisions—will soon be leaving the agency. Key report findings include: FDA drug approval costs have increased significantly over the past ten years, skyrocketing from roughly $30 million per medication in 2015 to more than $50 million in 2025. This only includes administrative costs borne by the agency—and taxpayers and drug sponsors by extension—and does not include billions of dollars in clinical trial expenses. Even as the FDA has more taxpayer dollars and user fees at its disposal, rejections are becoming increasingly common. The 2025 rejection rate of nearly 30 percent was near decade highs. The FDA's approach to five medications in particular (Ebvallo, ONS-5010, High-Dose Spinraza, Hetlioz, and Gefapixant) reflects continued risk aversion that harms consumers. Ross Marchand, Executive Director of the Taxpayers Protection Alliance, offered the following comment: "For too long, the FDA has stood in between patients and life-saving treatments. New leaders at the helm of the Department of Health and Human Services (HHS) and FDA, such as Robert F. Kennedy Jr. and Dr. Marty Makary, have promised to make America healthier and bolster patient access to care. This report shows that is simply not happening, and millions of Americans are paying the price. Bureaucrats need to get out of the way and put patients first. "There are plenty of steps the FDA and Congress can take to improve the drug approval process and expand access. Promising reforms include approval reciprocity with other nations, embracing a wider variety of outcomes-based data, and allowing more medications to be sold over the counter. With the right combination of changes, long-stalled drugs can finally come to market and be easily accessed by patients. "It's long past time for FDA reform. Policymakers need to step up and do right by patients. Millions of Americans will benefit from a faster and more reliable drug approval process." The Taxpayers Protection Alliance (TPA) is a non-profit, non-partisan organization dedicated to educating the public through the research, analysis, and dissemination of information on the government's impact on the economy. SOURCE Taxpayers Protection Alliance 21% more press release views with Request a Demo